Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1987 Jan;205(1):13–17. doi: 10.1097/00000658-198701000-00003

Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia.

S J Mentzer, R T Osteen, H F Starnes, W C Moloney, D Rosenthal, G Canellos, R E Wilson
PMCID: PMC1492871  PMID: 2432841

Abstract

The chronic leukemias are associated with significant morbidity from splenic enlargement and hyperfunction. Although some patients with chronic leukemia benefit from splenectomy, the indications for operation are unclear. To identify those patients who benefit most from splenectomy, nine patients with chronic lymphocytic leukemia (CLL) and eight patients with chronic granulocytic leukemia (CGL) who had splenectomy to palliate the symptoms of massive splenic bulk or to improve the hematologic sequelae of splenic hyperfunction were studied. Splenectomy for bulk symptoms provided good palliation of symptoms, but the duration of the benefit was limited by the stage of the disease. Five of eight patients with CGL with bulk symptoms died within 6 months of operation. Splenectomy for hyperfunction was limited to a short-term hematologic response. In three of four patients with CLL who were Coombs positive, the presence of autoantibodies correlated with a recurrent transfusion requirement within 3 months of splenectomy. Thus, the benefit of splenectomy for bulk symptoms must be weighed against the risk of surgery and the patient's limited life expectancy. The benefit of splenectomy for treatment of splenic hyperfunction depends on the stimulus to hyperfunction and may not be beneficial for patients with refractory autoimmune anemias.

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler S., Stutzman L., Sokal J., Mittelman A. Splenectomy for hematologic depression in lymphocytic lymphoma and leukemia. Cancer. 1975 Feb;35(2):521–528. doi: 10.1002/1097-0142(197502)35:2<521::aid-cncr2820350234>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  2. Castrini G., Pappalardo G. Splenectomy in early chronic myeloid leukemia. Int Surg. 1979 Nov-Dec;64(6):21–26. [PubMed] [Google Scholar]
  3. Christensen B. E., Hansen M. M., Videbaek A. Splenectomy in chronic lymphocytic leukaemia. Scand J Haematol. 1977 Apr;18(4):279–287. doi: 10.1111/j.1600-0609.1977.tb01197.x. [DOI] [PubMed] [Google Scholar]
  4. Coon W. W. The limited role of splenectomy in patients with leukemia. Surg Gynecol Obstet. 1985 Apr;160(4):291–294. [PubMed] [Google Scholar]
  5. Gomez G. A., Sokal J. E., Mittelman A., Aungst C. W. Splenectomy for palliation of chronic myelocytic leukemia. Am J Med. 1976 Jul;61(1):14–22. doi: 10.1016/0002-9343(76)90025-5. [DOI] [PubMed] [Google Scholar]
  6. JACOB H. S., MACDONALD R. A., JANDL J. H. REGULATION OF SPLEEN GROWTH AND SEQUESTERING FUNCTION. J Clin Invest. 1963 Sep;42:1476–1490. doi: 10.1172/JCI104832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. JANDL J. H., FILES N. M., BARNETT S. B., MACDONALD R. A. PROLIFERATIVE RESPONSE OF THE SPLEEN AND LIVER TO HEMOLYSIS. J Exp Med. 1965 Aug 1;122:299–326. doi: 10.1084/jem.122.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Karanas A., Silver R. T. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968 Sep;32(3):445–459. [PubMed] [Google Scholar]
  9. McBride C. M., Hester J. P. Chronic myelogenous leukemia: management of splenectomy in a high-risk population. Cancer. 1977 Feb;39(2):653–658. doi: 10.1002/1097-0142(197702)39:2<653::aid-cncr2820390242>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  10. Merl S. A., Theodorakis M. E., Goldberg J., Gottlieb A. J. Splenectomy for thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol. 1983 Nov;15(3):253–259. doi: 10.1002/ajh.2830150306. [DOI] [PubMed] [Google Scholar]
  11. Pearson H. A., Johnston D., Smith K. A., Touloukian R. J. The born-again spleen. Return of splenic function after splenectomy for trauma. N Engl J Med. 1978 Jun 22;298(25):1389–1392. doi: 10.1056/NEJM197806222982504. [DOI] [PubMed] [Google Scholar]
  12. Rubinstein D. B., Longo D. L. Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications. Am J Med. 1981 Oct;71(4):729–732. doi: 10.1016/0002-9343(81)90243-6. [DOI] [PubMed] [Google Scholar]
  13. Sadamori N., Sandberg A. A. Chromosome changes and splenectomy in Ph1-positive CML. II. Prognostic aspects in the blastic phase. Cancer Genet Cytogenet. 1984 Aug;12(4):303–308. doi: 10.1016/0165-4608(84)90063-3. [DOI] [PubMed] [Google Scholar]
  14. Schafer A. I., Miller J. B., Lester E. P., Bowers T. K., Jacob H. S. Monoclonal gammopathy in hereditary spherocytosis: a possible pathogenetic relation. Ann Intern Med. 1978 Jan;88(1):45–46. doi: 10.7326/0003-4819-88-1-45. [DOI] [PubMed] [Google Scholar]
  15. Schilling R. F. Hereditary spherocytosis: a study of splenectomized persons. Semin Hematol. 1976 Jul;13(3):169–176. [PubMed] [Google Scholar]
  16. Spiers A. S. Chronic granulocytic leukaemia and chronic lymphocytic leukaemia. Br Med J. 1974 Nov 23;4(5942):460–462. doi: 10.1136/bmj.4.5942.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wolf D. J., Silver R. T., Coleman M. Splenectomy in chronic myeloid leukemia. Ann Intern Med. 1978 Nov;89(5 Pt 1):684–689. doi: 10.7326/0003-4819-89-5-684. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES